Catalog of 5' fusion partners in NSCLC Circa 2020.

Since the discovery of fusion-positive () NSCLC around late 2011 to early 2012, clinical trials of multikinase inhibitors and highly potent and selective RET tyrosine kinase inhibitors have indicated that fusion is an actionable oncogenic driver in NSCLC. There seems to be a differential response to multikinase inhibitors depending on the fusion partner ( versus non-); thus, knowledge of the fusion partners in NSCLC is important. To date, we identified 48 unique fusion partners in from published literature and congress proceedings. Two of the novel fusion partners ( and ) were identified in fusions that emerged as resistant to EGFR tyrosine kinase inhibitors. In addition, multiple intergenic rearrangements were identified.